31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      FEMS Microbiology Reviews
      Oxford University Press
      Candida, Candida infections, antifungal immunity, microbiota, mycobiota, fungus-host-microbiota interactions, patient variability, fungal variability, microbiota variability

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.

          Abstract

          The complexity and variability of FunHoMic interactions between the fungal pathogen, its human host and the Microbiota strongly influence the development and outcomes of the superficial and systemic Candida albicans infections that plague human health worldwide.

          Related collections

          Most cited references953

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Structure, Function and Diversity of the Healthy Human Microbiome

          Studies of the human microbiome have revealed that even healthy individuals differ remarkably in the microbes that occupy habitats such as the gut, skin, and vagina. Much of this diversity remains unexplained, although diet, environment, host genetics, and early microbial exposure have all been implicated. Accordingly, to characterize the ecology of human-associated microbial communities, the Human Microbiome Project has analyzed the largest cohort and set of distinct, clinically relevant body habitats to date. We found the diversity and abundance of each habitat’s signature microbes to vary widely even among healthy subjects, with strong niche specialization both within and among individuals. The project encountered an estimated 81–99% of the genera, enzyme families, and community configurations occupied by the healthy Western microbiome. Metagenomic carriage of metabolic pathways was stable among individuals despite variation in community structure, and ethnic/racial background proved to be one of the strongest associations of both pathways and microbes with clinical metadata. These results thus delineate the range of structural and functional configurations normal in the microbial communities of a healthy population, enabling future characterization of the epidemiology, ecology, and translational applications of the human microbiome.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Diet rapidly and reproducibly alters the human gut microbiome

            Long-term diet influences the structure and activity of the trillions of microorganisms residing in the human gut 1–5 , but it remains unclear how rapidly and reproducibly the human gut microbiome responds to short-term macronutrient change. Here, we show that the short-term consumption of diets composed entirely of animal or plant products alters microbial community structure and overwhelms inter-individual differences in microbial gene expression. The animal-based diet increased the abundance of bile-tolerant microorganisms (Alistipes, Bilophila, and Bacteroides) and decreased the levels of Firmicutes that metabolize dietary plant polysaccharides (Roseburia, Eubacterium rectale, and Ruminococcus bromii). Microbial activity mirrored differences between herbivorous and carnivorous mammals 2 , reflecting trade-offs between carbohydrate and protein fermentation. Foodborne microbes from both diets transiently colonized the gut, including bacteria, fungi, and even viruses. Finally, increases in the abundance and activity of Bilophila wadsworthia on the animal-based diet support a link between dietary fat, bile acids, and the outgrowth of microorganisms capable of triggering inflammatory bowel disease 6 . In concert, these results demonstrate that the gut microbiome can rapidly respond to altered diet, potentially facilitating the diversity of human dietary lifestyles.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic.

              An expert panel was convened in October 2013 by the International Scientific Association for Probiotics and Prebiotics (ISAPP) to discuss the field of probiotics. It is now 13 years since the definition of probiotics and 12 years after guidelines were published for regulators, scientists and industry by the Food and Agriculture Organization of the United Nations and the WHO (FAO/WHO). The FAO/WHO definition of a probiotic--"live microorganisms which when administered in adequate amounts confer a health benefit on the host"--was reinforced as relevant and sufficiently accommodating for current and anticipated applications. However, inconsistencies between the FAO/WHO Expert Consultation Report and the FAO/WHO Guidelines were clarified to take into account advances in science and applications. A more precise use of the term 'probiotic' will be useful to guide clinicians and consumers in differentiating the diverse products on the market. This document represents the conclusions of the ISAPP consensus meeting on the appropriate use and scope of the term probiotic.
                Bookmark

                Author and article information

                Contributors
                Journal
                FEMS Microbiol Rev
                FEMS Microbiol Rev
                femsre
                FEMS Microbiology Reviews
                Oxford University Press
                0168-6445
                1574-6976
                24 November 2020
                May 2021
                24 November 2020
                : 45
                : 3
                : fuaa060
                Affiliations
                Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur , USC 2019 INRA, 25, rue du Docteur Roux, 75015 Paris, France
                Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen , Ashgrove Road West, Foresterhill, Aberdeen AB25 2ZD, UK
                BIOASTER Microbiology Technology Institute , 40 avenue Tony Garnier, 69007 Lyon, France
                Université de Paris , Sorbonne Paris Cité, 25, rue du Docteur Roux, 75015 Paris, France
                Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute , Beutenbergstraße 11a, 07745 Jena, Germany
                Institute of Microbiology, Friedrich Schiller University , Neugasse 25, 07743 Jena, Germany
                Gut Microbiology Group, Rowett Institute, University of Aberdeen , Ashgrove Road West, Foresterhill, Aberdeen AB25 2ZD, UK
                Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur , USC 2019 INRA, 25, rue du Docteur Roux, 75015 Paris, France
                Université de Paris , Sorbonne Paris Cité, 25, rue du Docteur Roux, 75015 Paris, France
                Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur , USC 2019 INRA, 25, rue du Docteur Roux, 75015 Paris, France
                Université de Paris , Sorbonne Paris Cité, 25, rue du Docteur Roux, 75015 Paris, France
                ProDigest BV , Technologiepark 94, B-9052 Gent, Belgium
                Center for Microbial Ecology and Technology (CMET), Department of Biotechnology, Faculty of Bioscience Engineering, Ghent University , Coupure Links, 9000 Ghent, Belgium
                Immunology Section, Vetsuisse Faculty, University of Zurich , Winterthurerstrasse 266a, Zurich 8057, Switzerland
                Institute of Experimental Immunology, University of Zurich , Winterthurerstrasse 190, Zürich 8057, Switzerland
                Mimetas, Biopartner Building 2, J.H. Oortweg 19, 2333 CH Leiden, The Netherlands
                Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center , Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
                Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute , Beutenbergstraße 11a, 07745 Jena, Germany
                Gut Microbiome Group, Vall d'Hebron Institut de Recerca (VHIR) , Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119–129, 08035 Barcelona, Spain
                Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur , USC 2019 INRA, 25, rue du Docteur Roux, 75015 Paris, France
                Magic Bullet Consulting , Biddlecombe House, Ugbrook, Chudleigh Devon, TQ130AD, UK
                BIOASTER Microbiology Technology Institute , 40 avenue Tony Garnier, 69007 Lyon, France
                Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur , USC 2019 INRA, 25, rue du Docteur Roux, 75015 Paris, France
                Université Clermont Auvergne , INRAE, VetAgro Sup, UMRF0545, 20 Côte de Reyne, 15000 Aurillac, France
                Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute , Beutenbergstraße 11a, 07745 Jena, Germany
                Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute , Beutenbergstraße 11a, 07745 Jena, Germany
                Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute , Beutenbergstraße 11a, 07745 Jena, Germany
                Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur , USC 2019 INRA, 25, rue du Docteur Roux, 75015 Paris, France
                Immunology Section, Vetsuisse Faculty, University of Zurich , Winterthurerstrasse 266a, Zurich 8057, Switzerland
                Institute of Experimental Immunology, University of Zurich , Winterthurerstrasse 190, Zürich 8057, Switzerland
                Gut Microbiome Group, Vall d'Hebron Institut de Recerca (VHIR) , Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119–129, 08035 Barcelona, Spain
                Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen , Ashgrove Road West, Foresterhill, Aberdeen AB25 2ZD, UK
                Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center , Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
                Mimetas, Biopartner Building 2, J.H. Oortweg 19, 2333 CH Leiden, The Netherlands
                NEXBIOME Therapeutics, 22 allée Alan Turing , 63000 Clermont-Ferrand, France
                BIOASTER Microbiology Technology Institute , 40 avenue Tony Garnier, 69007 Lyon, France
                NEXBIOME Therapeutics, 22 allée Alan Turing , 63000 Clermont-Ferrand, France
                ProDigest BV , Technologiepark 94, B-9052 Gent, Belgium
                Gut Microbiology Group, Rowett Institute, University of Aberdeen , Ashgrove Road West, Foresterhill, Aberdeen AB25 2ZD, UK
                MRC Centre for Medical Mycology, Department of Biosciences, University of Exeter , Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, UK
                Author notes
                Corresponding author: Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur, 25–28 rue du Docteur Roux, 75015 Paris, France. E-mail: christophe.denfert@ 123456pasteur.fr
                Corresponding author: MRC Centre for Medical Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, UK. E-mail: a.j.p.brown@ 123456exeter.ac.uk
                Author information
                https://orcid.org/0000-0002-6235-3886
                https://orcid.org/0000-0003-2992-2503
                https://orcid.org/0000-0003-1406-4251
                Article
                fuaa060
                10.1093/femsre/fuaa060
                8100220
                33232448
                a6eaf19b-a697-4c93-88c0-c56f08a0b7ba
                © The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 03 October 2020
                : 18 November 2020
                Page count
                Pages: 55
                Funding
                Funded by: Swiss National Science Foundation, DOI 10.13039/501100001711;
                Award ID: CRSII5_173863
                Funded by: Deutsche Forschungsgemeinschaft, DOI 10.13039/501100001659;
                Award ID: 434385622/GR 5617/1-1
                Award ID: 532/20-1
                Funded by: Wellcome Trust, DOI 10.13039/100010269;
                Award ID: 215599/Z/19/Z
                Funded by: Medical Research Council, DOI 10.13039/501100000265;
                Award ID: MR/N006364/1
                Categories
                Review Article
                AcademicSubjects/SCI01150

                Microbiology & Virology
                candida,candida infections,antifungal immunity,microbiota,mycobiota,fungus-host-microbiota interactions,patient variability,fungal variability,microbiota variability

                Comments

                Comment on this article